Our History

Boyalife is awarded as 2020 China’s New Health Enterprise

ThermoGenesis receives acknowledgement letter from FDA allowing Its SARS-CoV-2 (COVID-19) IgM/IgG antibody fast detection kit for distribution.

Boyalife’s stem cell bank in Tianjin officially operates

Boyalife join hands with Bureau of Science and Technology of Wuxi Municipality to launch the cell therapy industry alliance initiative

Boyalife signs a framework agreement for regenerative medicine with Wuxi People’s Hospital.

Boyalife’s cutting-edge technology unveils at the Xi’an Global Hard&Core Technology Industry Expo 2018

Boyalife wins the title of “The Most Potential Venture High-tech Company of Technological Talent Entrepreneurship”

ThermoGenesis Crop entered the market of  CAR-T  Related Contract Development and Manufacturing (CDMO) Services.

Boyalife signs a formal agreement with Fujita Health University to build the Fujita-Boyalife International Research Center for Regenerative Medicine in Japan.

Cesca Therapeutics, a Boyalife company, acquires SynGen to expand its capabilities in the processing of high-value target cells.

Boyalife establishes the ThermoGenesis Corp. subsidiary under Cesca to further strengthen its device business.

Boyalife treats the world’s first case of Cockayne Syndrome through the use of placenta-derived stem cells.

Boyalife Group establishes a global award, the Boyalife Science Translational Medicine Award in Stem Cell and Regenerative Medicine.

Boyalife Group acquires 17% ownership in Nuo Therapeutics Inc. (NASDAQ:AURX)

Boyalife Group acquires 70% equity ownership in Cesca Therapeutics Inc. (NASDAQ:KOOL), a US-based leader in automatic cellular processing and autologous cell-based therapies.

Boyalife Group wins the National R&D Leadership Award. Boyalife Genomics opens a cloning facility in Tianjin for cattle breeding.

Boyalife Group obtains a seat on the board of Sooam Biotech Research Foundation.

Boyalife Genimics clones the first Chinese Tibetan Mastiff.

Chairman Dr. Xiaochun “Chris” Xu wins the 2013 China Economic Figure Award.

BoyaLife Group wins the Prestigious 2012 CCTV China Brand Award.

Peking University and Boyalife jointly form the PKU-Boyalife Institute of Translational Medicine.

Peking University acquires a 40% position in Bejing Boyalife Stem Cell.

Dr. Ruiping Xiao, the founding director of the Institute of Molecular Medicine at Peking University (IMM-PKU), became a chief scientist of INCOSC.

Boyalife signed a strategic partnership agreement with the Institute of Molecular Medicine at Peking University.

Boyalife Stem Cell Bank was established and accredited by NRL and CAP. It has become the #1 recognized brand by stem cell professionals in China.

INCOSC was founded and supported by several major grants from the Chinese Ministry of Science & Technology (MOST) and local governments to foster collaborations among a number of top universities and research institutes. INCOSC later evolved into the Boyalife Group.